P1-06-12: Circulating Tumor Cells (CTC) Monitoring during Phase II Study with Lapatinib (L) and Capecitabine (C) in Patients with Brain Metastases from HER2−Positive (+) Metastatic Breast Cancer (MBC) before Whole Brain Radiotherapy (WBR): LANDSCAPE Study.

Brain Metastases ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Phase Ii Study ◽

Metastatic Breast ◽

Whole Brain Radiotherapy ◽

Her2 Positive ◽

Brain Radiotherapy

LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.509 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 509-509 ◽

Cited By ~ 18

Author(s):

T. D. Bachelot ◽

G. Romieu ◽

M. Campone ◽

V. Dieras ◽

C. Cropet ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Whole Brain Radiotherapy ◽

Her2 Positive ◽

Whole Brain ◽

Brain Radiotherapy

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

Breast Cancer Research and Treatment ◽

10.1007/s10549-012-2045-1 ◽

2012 ◽

Vol 134 (1) ◽

pp. 283-289 ◽

Cited By ~ 70

Author(s):

Marta Pestrin ◽

Silvia Bessi ◽

Fabio Puglisi ◽

Alessandro M. Minisini ◽

Giovanna Masci ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Single Agent ◽

Metastatic Breast ◽

Proof Of Concept ◽

Her2 Positive ◽

Multicenter Phase

OT1-02-06: DETECT III – A Multicenter, Randomized, Phase III Study To Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2−Negative Metastatic Breast Cancer and HER2−Positive Circulating Tumor Cells.

10.1158/0008-5472.sabcs11-ot1-02-06 ◽

2011 ◽

Cited By ~ 1

Author(s):

CA Melcher ◽

W Janni ◽

U Ortmann ◽

B Jäger ◽

B Rack ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Standard Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Study

PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.

10.1158/0008-5472.sabcs11-pd05-07 ◽

2011 ◽

Author(s):

EM Olson ◽

LM Flores ◽

JS Najita ◽

C Curley ◽

J Jeong ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker

BMC Cancer ◽

10.1186/1471-2407-13-202 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 41

Author(s):

Yi Liu ◽

Qian Liu ◽

Tao Wang ◽

Li Bian ◽

Shaohua Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽

Predictive Biomarker ◽

Breast Cancer Patients ◽

Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-011-0260-0 ◽

2011 ◽

Vol 17 (2) ◽

pp. 96-104 ◽

Cited By ~ 54

Author(s):

Naoki Hayashi ◽

Seigo Nakamura ◽

Yasuharu Tokuda ◽

Yuji Shimoda ◽

Hiroshi Yagata ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Prognostic Value ◽

Metastatic Breast ◽

Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy

Annals of Oncology ◽

10.1093/annonc/mdr434 ◽

2012 ◽

Vol 23 (5) ◽

pp. 1144-1150 ◽

Cited By ~ 67

Author(s):

A. Giordano ◽

M. Giuliano ◽

M. De Laurentiis ◽

G. Arpino ◽

S. Jackson ◽

...

Keyword(s):

Breast Cancer ◽

Targeted Therapy ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽

Abstract OT2-6-10: DETECT IV – A multicenter, single arm, phase II study evaluating the efficacy of everolimus in combination with endocrine therapy in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and HER2-negative circulating tumor cells (CTCs)

10.1158/0008-5472.sabcs13-ot2-6-10 ◽

2013 ◽

Author(s):

F Schochter ◽

C Melcher ◽

C Hagenbeck ◽

TWP Friedl ◽

B Jäger ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Hormone Receptor Positive

Abstract P2-16-02: Bevacizumab, etoposide, and cisplatin (BEEP) is highly effective in brain metastases of HER2 positive breast cancer progressing from whole brain radiotherapy - Subgroup analysis of a multi-center phase II study

10.1158/0008-5472.sabcs13-p2-16-02 ◽

2013 ◽

Author(s):

Y-S Lu ◽

W-W Chen ◽

C-H Lin ◽

D-C Yeh ◽

L-M Tseng ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Subgroup Analysis ◽

Phase Ii Study ◽

Whole Brain Radiotherapy ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Brain Radiotherapy ◽

Positive Breast Cancer

Abstract P3-01-08: HER2-negative metastatic breast cancer with HER2-positive circulating tumor cells (CTCs): A new CTC-defined HER2-positive subgroup

10.1158/1538-7445.sabcs18-p3-01-08 ◽

2019 ◽

Author(s):

AN Shah ◽

L Gerratana ◽

Q Zhang ◽

AA Davis ◽

Y Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Metastatic Breast ◽